{
    "id": 2787,
    "fullName": "HSBP1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HSBP1 over exp indicates an over expression of the HSBP1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3281,
        "geneSymbol": "HSBP1",
        "terms": [
            "HSBP1",
            "NPC-A-13"
        ]
    },
    "variant": "over exp",
    "createDate": "12/18/2014",
    "updateDate": "03/20/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1487,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells that overexpressed HSBP1 demonstrated resistance to Abraxane (paclitaxel) in androgen-withdrawl cell culture conditions, and in castrated cell line xenograft models (PMID: 20101233)",
            "molecularProfile": {
                "id": 2601,
                "profileName": "HSBP1 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1385,
                    "pubMedId": 20101233,
                    "title": "Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20101233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1489,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OGX-427 increased sensitivity to Gemzar (gemcitabine) in pancreatic cancer cells overexpressing HSBP1 in culture and in cell line xenograft models (PMID: 22012255).",
            "molecularProfile": {
                "id": 2601,
                "profileName": "HSBP1 over exp"
            },
            "therapy": {
                "id": 1808,
                "therapyName": "Gemcitabine + OGX-427",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1386,
                    "pubMedId": 22012255,
                    "title": "OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22012255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1488,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OGX-427 inhibited proliferation and induced apoptosis in pancreatic cancer cells overexpressing HSBP1 in culture and in cell line xenograft models (PMID: 22012255).",
            "molecularProfile": {
                "id": 2601,
                "profileName": "HSBP1 over exp"
            },
            "therapy": {
                "id": 1807,
                "therapyName": "OGX-427",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1386,
                    "pubMedId": 22012255,
                    "title": "OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22012255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2601,
            "profileName": "HSBP1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}